ADXN
vs
S&P 500
ADXN
S&P 500
Over the past 12 months, ADXN has underperformed S&P 500, delivering a return of -17% compared to the S&P 500's +14% growth.
Stocks Performance
ADXN vs S&P 500
Performance Gap
ADXN vs S&P 500
Performance By Year
ADXN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Addex Therapeutics Ltd
Glance View
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
